<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>According to the <z:hpo ids='HP_0001428'>somatic mutation</z:hpo> theory (SMT), <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> begins with a genetic change in a single cell that passes it on to its progeny, thereby generating a clone of malignant cells </plain></SENT>
<SENT sid="1" pm="."><plain>It is strongly supported by observations of <z:hpo ids='HP_0001909'>leukemias</z:hpo> that bear specific chromosome translocations, such as Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, in which a translocation activates the c-myc gene, and <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>), in which the Philadelphia chromosome causes production of the BCR-ABL oncoprotein </plain></SENT>
<SENT sid="2" pm="."><plain>Although the SMT has been modified and extended to encompass <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor genes, epigenetic <z:hpo ids='HP_0000005'>inheritance</z:hpo>, and <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumor progression</z:e> through accumulation of further mutations, perhaps the strongest validation comes from the successful treatment of certain <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> with drugs that directly target the product of the mutant gene </plain></SENT>
</text></document>